ANALYSIS

SEN-B

Max Gurtler

2024-05-27

## Loading required package: pacman

# TABLE 1

|  | **CCA Result** | |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Female**, N = 372*1* | **Male**, N = 427*1* | **Total** (N = 799)*1* | **p-value***2* |
| **Screening Year** |  |  |  | 0.46 |
| 2019 | 42 / 372 (11%) | 40 / 427 (9.4%) | 82 / 799 (10%) |  |
| 2020 | 29 / 372 (7.8%) | 30 / 427 (7.0%) | 59 / 799 (7.4%) |  |
| 2021 | 183 / 372 (49%) | 226 / 427 (53%) | 409 / 799 (51%) |  |
| 2022 | 117 / 372 (31%) | 126 / 427 (30%) | 243 / 799 (30%) |  |
| 2023 | 1 / 372 (0.3%) | 5 / 427 (1.2%) | 6 / 799 (0.8%) |  |
| **Age** |  |  |  | 0.98 |
| 18-31 | 179 / 372 (48%) | 205 / 427 (48%) | 384 / 799 (48%) |  |
| >31 | 193 / 372 (52%) | 222 / 427 (52%) | 415 / 799 (52%) |  |
| **Origin** |  |  |  | 0.12 |
| <1% prevalence (non-endemic) | 143 / 366 (39%) | 130 / 414 (31%) | 273 / 780 (35%) |  |
| 1-9.9% prevalence (low) | 78 / 366 (21%) | 105 / 414 (25%) | 183 / 780 (23%) |  |
| 10-49% prevalence (moderate) | 103 / 366 (28%) | 124 / 414 (30%) | 227 / 780 (29%) |  |
| ≥50% prevalence (high) | 32 / 366 (8.7%) | 48 / 414 (12%) | 80 / 780 (10%) |  |
| Other Country | 10 / 366 (2.7%) | 7 / 414 (1.7%) | 17 / 780 (2.2%) |  |
| **Residence** |  |  |  | 0.49 |
| Dakar | 295 / 372 (79%) | 347 / 427 (81%) | 642 / 799 (80%) |  |
| Outside | 77 / 372 (21%) | 80 / 427 (19%) | 157 / 799 (20%) |  |
| **Alcohol Consumption** |  |  |  | 0.002 |
| Yes\_past | 3 / 361 (0.8%) | 18 / 404 (4.5%) | 21 / 765 (2.7%) |  |
| No | 358 / 361 (99%) | 386 / 404 (96%) | 744 / 765 (97%) |  |
| **AUDIT-C Score** |  |  |  | 0.037 |
| Misuse | 3 / 372 (0.8%) | 12 / 427 (2.8%) | 15 / 799 (1.9%) |  |
| Negative | 369 / 372 (99%) | 415 / 427 (97%) | 784 / 799 (98%) |  |
| **Dipstick EtG** |  |  |  | 0.49 |
| Negative | 261 / 329 (79%) | 319 / 392 (81%) | 580 / 721 (80%) |  |
| Positive | 68 / 329 (21%) | 73 / 392 (19%) | 141 / 721 (20%) |  |
| **Drug Consumption** |  |  |  | <0.001 |
| Yes\_now | 0 / 372 (0%) | 0 / 427 (0%) | 0 / 799 (0%) |  |
| Yes\_past | 0 / 372 (0%) | 13 / 427 (3.0%) | 13 / 799 (1.6%) |  |
| No | 372 / 372 (100%) | 414 / 427 (97%) | 786 / 799 (98%) |  |
| **Smoking** |  |  |  | <0.001 |
| Yes\_now | 2 / 372 (0.5%) | 16 / 427 (3.7%) | 18 / 799 (2.3%) |  |
| Yes\_past | 2 / 372 (0.5%) | 69 / 427 (16%) | 71 / 799 (8.9%) |  |
| No | 368 / 372 (99%) | 342 / 427 (80%) | 710 / 799 (89%) |  |
| **Hypertension** | 83 / 372 (22%) | 109 / 427 (26%) | 192 / 799 (24%) | 0.29 |
| **Diabetes** | 9 / 372 (2.4%) | 13 / 427 (3.0%) | 22 / 799 (2.8%) | 0.59 |
| **BMI** |  |  |  | <0.001 |
| Normal Weight | 170 / 365 (47%) | 289 / 426 (68%) | 459 / 791 (58%) |  |
| Underweight | 44 / 365 (12%) | 73 / 426 (17%) | 117 / 791 (15%) |  |
| Overweight | 98 / 365 (27%) | 58 / 426 (14%) | 156 / 791 (20%) |  |
| Obesity | 53 / 365 (15%) | 6 / 426 (1.4%) | 59 / 791 (7.5%) |  |
| **Dyslipidemia** | 157 / 372 (42%) | 160 / 427 (37%) | 317 / 799 (40%) | 0.17 |
| **Family History of Liver Disease** | 7 / 372 (1.9%) | 8 / 427 (1.9%) | 15 / 799 (1.9%) | >0.99 |
| **Family History of HCC** | 56 / 372 (15%) | 45 / 427 (11%) | 101 / 799 (13%) | 0.055 |
| **HBV viral load** |  |  |  | 0.081 |
| ≤20 IU/mL | 81 / 372 (22%) | 69 / 427 (16%) | 150 / 799 (19%) |  |
| 21-2000 IU/mL | 200 / 372 (54%) | 235 / 427 (55%) | 435 / 799 (54%) |  |
| 2001-20000 IU/mL | 66 / 372 (18%) | 78 / 427 (18%) | 144 / 799 (18%) |  |
| ≥20000 IU/mL | 25 / 372 (6.7%) | 45 / 427 (11%) | 70 / 799 (8.8%) |  |
| **qAgHBs** |  |  |  | 0.81 |
| <100 IU/mL | 33 / 372 (8.9%) | 38 / 427 (8.9%) | 71 / 799 (8.9%) |  |
| 100-1000 IU/mL | 44 / 372 (12%) | 57 / 427 (13%) | 101 / 799 (13%) |  |
| >1000 IU/mL | 295 / 372 (79%) | 332 / 427 (78%) | 627 / 799 (78%) |  |
| **AgHBe** |  |  |  | 0.073 |
| Negative | 367 / 372 (99%) | 413 / 427 (97%) | 780 / 799 (98%) |  |
| Positive | 5 / 372 (1.3%) | 14 / 427 (3.3%) | 19 / 799 (2.4%) |  |
| **HCV Serology** |  |  |  | 0.50 |
| Negative | 372 / 372 (100%) | 425 / 427 (100%) | 797 / 799 (100%) |  |
| Positive | 0 / 372 (0%) | 2 / 427 (0.5%) | 2 / 799 (0.3%) |  |
| **HDV Serology** |  |  |  | 0.76 |
| Negative | 366 / 370 (99%) | 421 / 427 (99%) | 787 / 797 (99%) |  |
| Positive | 4 / 370 (1.1%) | 6 / 427 (1.4%) | 10 / 797 (1.3%) |  |
| **On TDF at Baseline** | 19 / 372 (5.1%) | 31 / 427 (7.3%) | 50 / 799 (6.3%) | 0.21 |
| **ALAT** |  |  |  | 0.024 |
| ≤40 IU/L | 357 / 372 (96%) | 390 / 427 (91%) | 747 / 799 (93%) |  |
| 41-80 IU/L | 12 / 372 (3.2%) | 26 / 427 (6.1%) | 38 / 799 (4.8%) |  |
| >80 IU/L | 3 / 372 (0.8%) | 11 / 427 (2.6%) | 14 / 799 (1.8%) |  |
| **APRI Score** |  |  |  | 0.015 |
| Fibrosis | 2 / 372 (0.5%) | 6 / 427 (1.4%) | 8 / 799 (1.0%) |  |
| No Fibrosis | 366 / 372 (98%) | 404 / 427 (95%) | 770 / 799 (96%) |  |
| Unknown | 4 / 372 (1.1%) | 17 / 427 (4.0%) | 21 / 799 (2.6%) |  |
| **FibroScan LSM** |  |  |  | <0.001 |
| F0-1 (no or mild fibrosis) | 359 / 372 (97%) | 347 / 427 (81%) | 706 / 799 (88%) |  |
| F2–3 (significant fibrosis) | 11 / 372 (3.0%) | 51 / 427 (12%) | 62 / 799 (7.8%) |  |
| F4 (cirrhosis) | 2 / 372 (0.5%) | 29 / 427 (6.8%) | 31 / 799 (3.9%) |  |
| **FibroScan CAP** |  |  |  | 0.55 |
| SLD | 34 / 372 (9.1%) | 34 / 427 (8.0%) | 68 / 799 (8.5%) |  |
| Normal | 338 / 372 (91%) | 393 / 427 (92%) | 731 / 799 (91%) |  |
| **UPCR Ratio** |  |  |  | 0.013 |
| Proteinuria (>0.2 mg/mg) | 358 / 372 (96%) | 393 / 427 (92%) | 751 / 799 (94%) |  |
| Normal (<0.2 mg/mg) | 14 / 372 (3.8%) | 34 / 427 (8.0%) | 48 / 799 (6.0%) |  |
| **Leukocyturia (Urine Strips)** |  |  |  | <0.001 |
| Leukocyturia | 173 / 371 (47%) | 57 / 426 (13%) | 230 / 797 (29%) |  |
| Normal | 198 / 371 (53%) | 369 / 426 (87%) | 567 / 797 (71%) |  |
| **Hematuria (Urine Strips)** |  |  |  | <0.001 |
| Hematuria | 68 / 371 (18%) | 29 / 426 (6.8%) | 97 / 797 (12%) |  |
| Normal | 303 / 371 (82%) | 397 / 426 (93%) | 700 / 797 (88%) |  |
| **Proteinuria (Urine Strips)** |  |  |  | 0.62 |
| Proteinuria | 52 / 371 (14%) | 65 / 426 (15%) | 117 / 797 (15%) |  |
| Normal | 319 / 371 (86%) | 361 / 426 (85%) | 680 / 797 (85%) |  |
| **Traditional Medicine** |  |  |  | 0.61 |
| Plant | 119 / 372 (32%) | 148 / 427 (35%) | 267 / 799 (33%) |  |
| Oil/Powder | 1 / 372 (0.3%) | 2 / 427 (0.5%) | 3 / 799 (0.4%) |  |
| None | 252 / 372 (68%) | 277 / 427 (65%) | 529 / 799 (66%) |  |
| **eGFR** |  |  |  | <0.001 |
| ≥60 | 320 / 372 (86%) | 406 / 427 (95%) | 726 / 799 (91%) |  |
| 15-60 | 52 / 372 (14%) | 21 / 427 (4.9%) | 73 / 799 (9.1%) |  |
| **cca\_res** |  |  |  | 0.52 |
| Negative | 302 / 332 (91%) | 359 / 389 (92%) | 661 / 721 (92%) |  |
| Positive | 30 / 332 (9.0%) | 30 / 389 (7.7%) | 60 / 721 (8.3%) |  |
| *1*n / N (%) | | | | |
| *2*Fisher's exact test; Pearson's Chi-squared test | | | | |

# TABLE 2

## 78 observations missing `cca\_res` have been removed. To include these observations, use `forcats::fct\_na\_value\_to\_level()` on `cca\_res` column before passing to `tbl\_summary()`.